MARVEL BIOSCIENCES CORP.
$47,000.00 CAD
≈ 7 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- January 5, 2026 – March 30, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q4-1038358
Published purpose
MB-204 is a novel therapeutic candidate with the potential to treat pediatric neurodevelopmental disorders, including Autism, Rett syndrome, and Fragile X syndrome. Many of these patients experience swallowing difficulties or require feeding tubes, creating a need for child-friendly dosage forms. Through this project, Marvel will develop a liquid oral formulation of MB-204 suitable for syringe or tube dosage.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions